Using EAE as a model, Kaye et al. (112) showed that laquinimod, an oral drug currently being evaluated for treatment of relapsing and remitting MS, induced genes associated with the AHR pathway such as Cyp1a1 and Ahrr in both naive and EAE mice treated with laquinimod in vitro and Cyp1a1 in vivo. Here, AHR is linked to relapsing-remitting multiple sclerosis.